argenx to Host Virtual R&D Day on July 20, 2021
July 14, 2021 at 01:00 AM EDT
July 14, 2021
In addition to argenx management presentations, the live event will include a moderated panel discussion on the treatment paradigm and clinical unmet needs of the new efgartigimod indications, featuring:
To complement the live event, the Company is hosting a program microsite with additional resources, including:
Access to the microsite, including the live webcast of the virtual event, can be found on the Investors section of the argenx website at argenx.com/investors. A replay of the event will be available on the argenx website for approximately one year following the call.
Belgium 0800 389 13
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.
For further information, please contact: